Rating Alert: Barclays Gives Alexion Pharmaceuticals (NASDAQ:ALXN) a Better “Overweight” Rating

November 29, 2016 - By olga

Rating Alert:  Barclays Gives Alexion Pharmaceuticals (NASDAQ:ALXN) a Better

Alexion Pharmaceuticals (NASDAQ:ALXN) Upgrade

New York-listed Alexion Pharmaceuticals (NASDAQ:ALXN), was raised by research analysts at Barclays. The firm raised its rating on the $27.97B market cap company to a “Overweight” from a previous “Equal-Weight”.

Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) Ratings Coverage

Out of 20 analysts covering Alexion Pharmaceuticals Inc. (NASDAQ:ALXN), 15 rate it a “Buy”, 0 “Sell”, while 5 “Hold”. This means 75% are positive. $257 is the highest target while $82 is the lowest. The $177.47 average target is 42.93% above today’s ($124.17) stock price. Alexion Pharmaceuticals Inc. has been the topic of 40 analyst reports since July 27, 2015 according to StockzIntelligence Inc. The stock of Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) has “Buy” rating given on Wednesday, August 12 by Vetr. RBC Capital Markets initiated the shares of ALXN in a report on Wednesday, July 13 with “Outperform” rating. The firm has “Neutral” rating given on Friday, October 28 by Wedbush. As per Thursday, January 7, the company rating was initiated by Suntrust Robinson. The stock of Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) earned “Buy” rating by Stifel Nicolaus on Friday, July 29. The firm has “Overweight” rating by Morgan Stanley given on Friday, October 2. UBS maintained the stock with “Buy” rating in Thursday, February 4 report. Barclays Capital maintained the stock with “Equal-Weight” rating in Thursday, February 4 report. The firm earned “Overweight” rating on Tuesday, June 7 by Morgan Stanley. The stock of Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) earned “Neutral” rating by BTIG Research on Thursday, January 7.

About 1.67M shares traded hands. Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) has declined 22.49% since April 26, 2016 and is downtrending. It has underperformed by 27.75% the S&P500.

Analysts await Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) to report earnings on February, 1. They expect $1.10 EPS, up 30.95% or $0.26 from last year’s $0.84 per share. ALXN’s profit will be $247.83M for 28.23 P/E if the $1.10 EPS becomes a reality. After $1.18 actual EPS reported by Alexion Pharmaceuticals, Inc. for the previous quarter, Wall Street now forecasts -6.78% negative EPS growth.

Insitutional Activity: The institutional sentiment decreased to 1.07 in 2016 Q2. Its down 0.12, from 1.19 in 2016Q1. The ratio dropped, as 51 funds sold all Alexion Pharmaceuticals, Inc. shares owned while 155 reduced positions. 58 funds bought stakes while 188 increased positions. They now own 212.84 million shares or 4.67% less from 223.26 million shares in 2016Q1.

The Ontario – Canada-based Td Asset Mgmt has invested 0.08% in Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN). Toronto Dominion Bank & Trust last reported 1,239 shares in the company. Axa last reported 1.01 million shares in the company. Royal London Asset Mngmt Ltd, a United Kingdom-based fund reported 75,344 shares. Calamos Wealth Lc last reported 12,353 shares in the company. Moreover, Cubist Systematic Strategies Ltd Llc has 0.11% invested in Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) for 15,666 shares. Goldman Sachs Group Inc Inc reported 1.45M shares or 0.06% of all its holdings. Global X Mgmt Communications Ltd accumulated 61 shares or 0% of the stock. Stephens Investment Mgmt Gru Ltd Liability, a Texas-based fund reported 5,090 shares. Tudor Inv Et Al owns 13,329 shares or 0.03% of their US portfolio. Blackrock Japan Co Ltd, a Japan-based fund reported 285,868 shares. Marsico Capital Mgmt Limited Liability accumulated 0.08% or 20,877 shares. Chilton Ltd Liability last reported 31,005 shares in the company. Westpac Banking holds 0% or 31,884 shares in its portfolio. Ig Invest Mngmt Ltd last reported 0.02% of its portfolio in the stock.

Insider Transactions: Since June 13, 2016, the stock had 0 buys, and 19 sales for $9.39 million net activity. 222 shares with value of $30,445 were sold by Wagner Heidi L on Monday, August 8. Another trade for 650 shares valued at $82,089 was sold by O’Neill Julie. PARVEN ALVIN S sold $2.14M worth of stock. BELL LEONARD sold 37,317 shares worth $5.24M. Thiel Carsten had sold 3,225 shares worth $414,945 on Monday, September 12. Shares for $47,093 were sold by Miller Edward. Sinha Vikas sold 277 shares worth $37,988.

Alexion Pharmaceuticals, Inc. is a biopharmaceutical company. The company has a market cap of $27.97 billion. The Firm is focused on the development and commercialization of life-transforming therapeutic products. It has a 76.31 P/E ratio. The Firm operates through innovation, development and commercialization of life-transforming therapeutic products segment.

According to Zacks Investment Research, “Alexion Pharmaceuticals develops pharmaceutical products for the treatment of heart disease, and inflammation, diseases of the immune system and cancer in humans. The company’s lead product candidates are genetically altered antibodies that target specific diseases which arise when the human immune system induces undesired inflammation in the human body. These candidates are designed to block components of the human immune system which cause undesired inflammation while allowing beneficial components of the immune system to remain functional.”

ALXN Company Profile

Alexion Pharmaceuticals, Inc., incorporated on January 28, 1992, is a biopharmaceutical company. The Firm is focused on the development and commercialization of life-transforming therapeutic products. The Firm operates through innovation, development and commercialization of life-transforming therapeutic products segment. The Company’s marketed products include Soliris (eculizumab), Strensiq (asfotase alfa) and Kanuma (sebelipase alfa). The Company’s clinical programs include Soliris (eculizumab), ALXN 1101, ALXN 1007, SBC-103, ALXN 1210 and ALXN 5500.

More notable recent Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) news were published by: Nasdaq.com which released: “Lawsuit for Investors in Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) shares …” on November 29, 2016, also Businesswire.com with their article: “Robbins Arroyo LLP: Alexion Pharmaceuticals, Inc. (ALXN) Misled Shareholders …” published on November 22, 2016, Marketwatch.com published: “Alexion Pharma shares halted, company to delay quarterly results” on November 09, 2016. More interesting news about Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) were released by: Prnewswire.com and their article: “Harwood Feffer LLP Announces Investigation of Alexion Pharmaceuticals, Inc.” published on November 10, 2016 as well as Prnewswire.com‘s news article titled: “SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation …” with publication date: November 10, 2016.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By

Tags: , ,

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


Recent Market News

>